DESyne in Routine Clinical Practice

N/ATerminatedNCT02039713

Seung-Jung Park342 enrolled

Overview

The purpose of this study is to evaluate effectiveness and safety of DESyne in Routine Clinical Practice

Study Type

OBSERVATIONAL

Enrollment

342

Conditions

Angioplasty, Transluminal, Percutaneous Coronary Coronary Artery Disease

Interventions

DeSyne drug eluting stent groupDEVICE

Eligibility

Sex: ALLMin age: 20 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Age 20 and more * Intervention with DeSyne drug eluting coronary stent * Agreed with written informed consent form Exclusion Criteria: * Intervention with DeSyne drug eluting coronary stent and other drug eluting stent at the same time * Life expectancy of 1year and under * Cardiac shock

Locations (20)

Sam Anyang Hospital

Anyang, South Korea

Soon Chun Hyang University Hospital Bucheon

Cheonan, South Korea

Outcomes

Primary Outcomes

Composite event rate

Death, non fatal myocardial infarction, Target Vessel Revascularization

Time frame: 1year

Secondary Outcomes

All death

Time frame: 5year

Cardiac death

Time frame: 5year

Myocardial infarction

Time frame: 5year

Composite event of death or myocardial infarction

Time frame: 5year

Composite event of cardiac death or myocardial infarction

Time frame: 5year

Target Vessel revascularization

Time frame: 5year

Target Lesion revascularization

Time frame: 5year

Stent thrombosis

stent thrombosis as classified by an Academic Research Consortium

Time frame: 5year

Stroke

Time frame: 5year

Procedural success

defined as less than 30% residual stenosis at the completion of procedure without death or Q wave myocardial infarction or urgent revascularization participants will be followed for the duration of hospital stay, an expected average of 3days.

Time frame: 3day

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.